跳至主要内容
临床试验/IRCT20211012052743N1
IRCT20211012052743N1招募中3 期

Clinical trial study of safety and efficacy assessment of human umbilical cord matrix mesenchymal stem cell infusion on the treatment of new coronavirus 2019 pneumonia in humans

Cell Gene Medicine Company0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 85 years(—)
性别
All

入选标准

  • Patients in the acute phase with Laboratory confirmation of SARS-COV-2 infection with RT-PCR
  • Pneumonia confirmed by chest x-ray or Computed tomography Scan
  • Respiratory rate> 30 times/minute
  • Oxygen Saturation less than 93%
  • Arterial oxygen partial pressure (Pao2) /oxygen inhalation(Fio2) less than 300 mm Hg
  • No history of tumor or malignant disease
  • CRP greater than normal range

排除标准

  • Pregnant patient with a positive pregnancy test or during lactation or who is planning to become pregnant during the study
  • The definitive history of acquired or inherited immune deficiency diseases
  • The definitive psychotic illness, A history of serious mental illness or a history of suicide.
  • Any active or treated Cancerous diseases.
  • Creatinine greater than 1.7 mg/dL
  • Co-infection of human immunodeficiency viruses, Hepatitis B, Hepatitis C and Human T-lymphotropic virus
  • Any cardiac hemodynamic disorder
  • Positive PPD test
  • Positive syphilis test
  • Treatment with cytotoxic drugs one month prior study

研究者

发起方
Cell Gene Medicine Company

相似试验